<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="onto companion plates containing 500 μl of Krebs-HEPES buffer. Afterward," exact="dextran" post="conjugated with FITC (FITC-dextran 1 mg/ml) was added to"/>
 <result pre="various transcytosis inhibitors in different concentration, including 10 μM of" exact="nystatin" post="(Sigma), 10 μM of chlorpromazine hydrochloride (CPZ, Sigma), 20"/>
 <result pre="concentration, including 10 μM of nystatin (Sigma), 10 μM of" exact="chlorpromazine" post="hydrochloride (CPZ, Sigma), 20 μM of dimethyl amiloride (DMA,"/>
 <result pre="μM of chlorpromazine hydrochloride (CPZ, Sigma), 20 μM of dimethyl" exact="amiloride" post="(DMA, Sigma), and 10 μM of colchicine (Sigma). Drugs"/>
 <result pre="a series of pharmacological inhibitors including bafilomycin (BFA), MG132, and" exact="chloroquine" post="(CQ), which target either autophagic or proteasomal degradation pathways,"/>
 <result pre="cells, we pretreated barrier cells with pharmacological inhibitors including Nystatin," exact="chlorpromazine" post="(CPZ), and dimethyl amiloride (DMA), which specifically inhibit caveolae-dependent"/>
 <result pre="cells with pharmacological inhibitors including Nystatin, chlorpromazine (CPZ), and dimethyl" exact="amiloride" post="(DMA), which specifically inhibit caveolae-dependent endocytosis, clathrin-dependent endocytosis, and"/>
 <result pre="of both the placenta barrier and the BBB. Using fluorescence-tagged" exact="dextran" post="as an indicator, our results revealed that ZIKV infection"/>
</results>
